Home   Site Map   About Roche   Contact Us   Help   
nullnull
Clinical. Credible. Convenient.
Not a Member? Log In Forgot Password? Instant Access Code
Sign Up
»
 E-mail: Password: Code:
  Remember Me Log In
»
 Go
»
Main Menu
Rheumatoid Arthritis Home
News
Clinical Trials
Education
Publications
Other Resources
Meeting Calendar

Select a link below to view details.
Previous July 2010 Next
S M T W T F S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31
Rheumatoid Arthritis Clinical Trials

Rheumatoid Arthritis Clinical Trials Database
Real-time, comprehensive global Rheumatoid Arthritis clinical trials database

  • Global clinical development on a trial-by-trial basis
  • Search by any drug name
  • Search by any status and/or phase of the trial
 TrialTrove™Locked Content Click
Here		  
  What is this?
 
   
 
Roche Clinical Trials
 
Recruiting Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs and monotherapy who have an Inadequate Response to Current Non-Biologic or Biologic DMARDs
 
 
Recruiting International Multi-Center Open label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy.
 
 
Recruiting A randomized, active controlled, double-blind, study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera®)and tocilizumab (RoActemra®) versus tocilizumab in patients with active rheumatoid arthritis with an incomplete response to methotrexate
 
 
Recruiting Open-label, multicenter, randomized, parallel study to investigate pk, pd, efficacy and safety of tocilizumab (TCZ, RO4877533) following subcutaneous administration of TCZ 162 mg weekly or every other week in combination with methotrexate in patients with rheumatoid arthritis
 
 
Recruiting A 24 week randomized, double-blind, placebo-controlled withdrawal trial with a 16 week open-label lead-in phase, and 64 week open-label follow-up, to evaluate the effect on clinical response and the safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis.
 
 
Recruiting Randomized placebo-controlled study of two treatment strategies based on tocilizumab (TCZ) with or without methotrexate (MTX) and possible addition of other disease-modifying anti-rheumatic drugs (DMARDs) in patients...
 
 
Recruiting U-ACT-EARLY: A multi-center, randomized, double blind, placebo controlled study to evaluate remission in DMARD and biological naïve early reumatoid arthritis (RA) subjects treated with tocilizumab (TCZ) plus tight control methotrexate (MTX) , TCZ monotherapy or tight control MTX monotherapy
 
 
Recruiting A single-arm, open-label study of the safety and reduction of signs and symptoms during treatment with tocilizumab in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis
 
 
Recruiting Multi-center, randomized, double-blind, parallel group study of the safety, disease remission & prevention of structural joint damage during treatment with tocilizumab as a monotherapy & in combination with methotrexate versus methotrexate in pts with early moderate to severe rheumatoid arthritis
 
 
Recruiting An open-label, multi-center, one sequence cross-over drug interaction study to investigate the effect of tocilizumab (TCZ, RO4877533) on the pharmacokinetics and pharmacodynamics of an oral contraceptive (OC) in female patients with active rheumatoid arthritis (RA)
 
Clinical Trials Registry and Results
Roche-Trials.com » Visit Roche Trials for more information on completed Roche clinical studies.

ClinicalTrials.gov » ClinicalTrials.gov provides regularly updated information about federally and privately supported clinical research in human volunteers.

RocheInvestigators.com » RocheInvestigators.com: Investigators interested in applying to participate in the U.S. arm of global development clinical trials sponsored by Hoffmann-La Roche Inc., please click the link.